Tag Archives: Datroway and ivonescimab combination to enter Phase III study under new AstraZeneca, Daiichi Sankyo and Summit collaboration

AstraZeneca, Daiichi Sankyo and Summit plan Datroway–ivonescimab clinical programme across multiple cancers

Laboratory investigation of protein expression

The collaboration is set to begin with a Phase III trial in first-line triple-negative breast cancer, with the partners sharing trial costs while retaining rights to their respective medicines. IN BRIEFKEY TAKEAWAYSFAQs AstraZeneca and Daiichi Sankyo have entered into a … Read the full press release →